AstraZeneca Shares Plunge on Drug Trial Failure

The trial, which tested Wainua’s ability to reduce cardiovascular deaths and recurring heart events, did not achieve statistical significance.

Shares of the FTSE 100 giant fell sharply, dragging down the pharmaceutical sector.

The failure raises questions about AstraZeneca’s growth prospects.

Rival drugmakers Pfizer, Alnylam, and BridgeBio saw their shares rise on the news.